Evidence map›Paper›PMID 32974613›Full record

ArticleBlood cancer discovery2020

Persistence of Drug-Resistant Leukemic Stem Cells and Impaired NK Cell Immunity in CML Patients Depend on

Giovannino Silvestri, Rossana Trotta, Lorenzo Stramucci, Justin J Ellis, Jason G Harb, Paolo Neviani, Shuzhen Wang, Ann-Kathrin Eisfeld, Christopher J Walker, Bin Zhang and 28 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood cancer discovery, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 33 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. miR-181a plays the tumor-suppressor role in chronic myeloid leukemia CD34Cellular and molecular life sciences : CMLS · 2023
    Article
  8. Review
  9. Review
  10. Review
  11. Article
  12. Review
  13. Review
  14. Review
  15. Review
  16. Article
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

38 authors at 14 institutions in 6 countries.

Giovannino Silvestri *Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland.
Rossana Trotta *Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, Maryland.
Lorenzo StramucciDepartment of Medicine, University of Maryland School of Medicine, Baltimore, Maryland.
Justin J EllisDepartment of Molecular Virology Immunology and Medical Genetics, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.
Jason G HarbDepartment of Molecular Virology Immunology and Medical Genetics, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.
Paolo NevianiDepartment of Molecular Virology Immunology and Medical Genetics, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.
Shuzhen WangDepartment of Medicine, University of Maryland School of Medicine, Baltimore, Maryland.ORCID 0000-0003-3869-2463
Ann-Kathrin EisfeldDepartment of Molecular Virology Immunology and Medical Genetics, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.
Christopher J WalkerDepartment of Molecular Virology Immunology and Medical Genetics, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.
Bin ZhangDivision of Hematopoietic Stem Cell and Leukemia Research, City of Hope National Medical Center, Duarte, California.
Klara SrutovaInstitute of Hematology and Blood Transfusion, University of Prague, Prague, Czech Republic.
Carlo Gambacorti-PasseriniHematology and Clinical Research Unit, San Gerardo Hospital, Monza, Italy.
Gabriel PinedaDepartment of Health Sciences, School of Health and Human Services, National University, San Diego, California.
Catriona H M JamiesonDepartment of Medicine and Moores Cancer Center, University of California, San Diego, La Jolla, California.
Fabio StagnoDivision of Hematology and Unit of Medical Oncology, A.O.U. "Policlinico-Vittorio Emanuele", University of Catania, Catania, Italy.
Paolo VigneriDivision of Hematology and Unit of Medical Oncology, A.O.U. "Policlinico-Vittorio Emanuele", University of Catania, Catania, Italy.
Georgios NteliopoulosDepartment of Haematology, Hammersmith Hospital, Imperial College London, London, United Kingdom.
Philippa C MayDepartment of Haematology, Hammersmith Hospital, Imperial College London, London, United Kingdom.
Alistair G ReidDepartment of Haematology, Hammersmith Hospital, Imperial College London, London, United Kingdom.
Ramiro GarzonDepartment of Molecular Virology Immunology and Medical Genetics, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.
Denis-Claude RoyDepartment of Hematology and Cellular Therapy Laboratory, Hôpital Maisonneuve-Rosemont, University of Montreal, Montreal, Quebec, Canada.
Moutuaata M MoutuouDepartment of Hematology and Cellular Therapy Laboratory, Hôpital Maisonneuve-Rosemont, University of Montreal, Montreal, Quebec, Canada.
Martin GuimondDepartment of Hematology and Cellular Therapy Laboratory, Hôpital Maisonneuve-Rosemont, University of Montreal, Montreal, Quebec, Canada.
Peter HoklandDepartment of Hematology, Aarhus University Hospital, Aarhus, Denmark.
Michael W DeiningerDivision of Hematology and Hematologic Malignancies and Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah.
Garrett FitzgeraldCenter for Advanced Fetal Care University, University of Maryland School of Medicine, Baltimore, Maryland.
Christopher HarmanCenter for Advanced Fetal Care University, University of Maryland School of Medicine, Baltimore, Maryland.
Francesco DazziDivision of Cancer Studies, Rayne Institute, King's College London, London, United Kingdom.
Dragana MilojkovicDepartment of Haematology, Hammersmith Hospital, Imperial College London, London, United Kingdom.
Jane F ApperleyDepartment of Haematology, Hammersmith Hospital, Imperial College London, London, United Kingdom.
Guido MarcucciDivision of Hematopoietic Stem Cell and Leukemia Research, City of Hope National Medical Center, Duarte, California.
Jianfei QiMarlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, Maryland.
Katerina Machova PolakovaInstitute of Hematology and Blood Transfusion, University of Prague, Prague, Czech Republic.
Ying ZouMarlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, Maryland.
Xiaoxuan FanMarlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, Maryland.
Maria R BaerDepartment of Medicine, University of Maryland School of Medicine, Baltimore, Maryland.
Bruno CalabrettaSidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania.
Danilo PerrottiDepartment of Medicine, University of Maryland School of Medicine, Baltimore, Maryland. dperrotti@som.umaryland.edu.
University of Maryland, Baltimore · USThe Ohio State University · USHammersmith Hospital · GBHôpital Maisonneuve-Rosemont · CAAzienda Ospedaliero-Universitaria Policlinico - Vittorio Emanuele · ITCity Of Hope National Medical Center · USInstitute of Haematology and Blood Transfusion · CZAarhus University Hospital · DKAzienda Ospedaliera San Gerardo · ITHealth and Human Services Agency · USHuntsman Cancer Institute · USKing's College London · GBSidney Kimmel Cancer Center · USUniversity of California San Diego · US

Funding

Role of microRNAs in the regulation of CML stem cell survival and self renewalR01CA163800 · NCI · UNIVERSITY OF MARYLAND BALTIMORE · PI PERROTTI, DANILO · 2012 to 2017
$1.6M
NCI NIH HHS R01 CA163800
6 · The paper itself

Abstract

Persistence of drug-resistant quiescent leukemic stem cells (LSC) and impaired natural killer (NK) cell immune response account for relapse of chronic myelogenous leukemia (CML). Inactivation of protein phosphatase 2A (PP2A) is essential for CML-quiescent LSC survival and NK cell antitumor activity. Here we show that

Indexed as

Leukemia, Myelogenous, Chronic, BCR-ABL PositiveMicroRNAsHumansKiller Cells, NaturalNeoplastic Stem CellsProtein Kinase InhibitorsProtein Phosphatase 2Tumor MicroenvironmentMicroRNAsMIRN300 microRNA, humanProtein Kinase InhibitorsProtein Phosphatase 2

Identifiers

PMID32974613
PMCPMC7510943
OpenAlexW3009636168

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.